Oatly Group AB (publ)
28.9.2026 22:05:00 CEST | Globenewswire | Press release
Oatly to Report Third Quarter 2026 Financial Results on October 28, 2026
Oatly to Report Third Quarter 2026 Financial Results on October 28, 2026
MALMÖ, Sweden, September 28, 2026 – Oatly Group AB (publ) (Nasdaq: OTLY), the world’s original and largest oat drink company, will report financial results for the third quarter ended September 30, 2026, on Wednesday October 28, 2026 before the U.S. market opens. Oatly will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.
The conference call and simultaneous live webcast can be accessed on Oatly’s Investors website at https://investors.oatly.com under “Events.” The webcast will be archived for 30 days.
About Oatly
We are the world’s original and largest oat drink company. For over 30 years, we have exclusively focused on developing expertise around oats: a global power crop with inherent properties. Our commitment to oats has resulted in core technical advancements that enabled us to unlock the breadth of the dairy portfolio, including alternatives to milks, ice cream, yogurt, cooking creams, spreads and on-the-go drinks. Headquartered in Malmö, Sweden, the Oatly brand is available in more than 60 countries globally.
For more information, please visit www.oatly.com.
Contacts
investors@oatly.com
press@oatly.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Chemometec A/S5.10.2026 21:52:21 CEST | Press release
Major shareholder announcement - BlackRock, Inc.
Chemometec A/S5.10.2026 21:52:21 CEST | Pressemeddelelse
Storaktionærmeddelelse - BlackRock, Inc.
Tryg A/S5.10.2026 21:21:26 CEST | Pressemeddelelse
Storaktionærmeddelelse
Tryg A/S5.10.2026 21:21:26 CEST | Press release
Major Shareholder Announcement
Genmab A/S5.10.2026 20:49:00 CEST | Press release
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom